Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...

Insulin: Dosing Regimen and Adverse Effects

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...

Oral Hypoglycemic Agents: Biguanides and Glitazones

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...

Glucose Homeostasis: Pancreatic Islets and Insulin Secretion

Glucose Homeostasis: Pancreatic Islets and Insulin Secretion

The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...

Hypoglycemia and Glucagon

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...

Type I Diabetes I: Introduction

Type I Diabetes I: Introduction

Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

The hidden link between diabetes and dementia: Findings from recent epidemiological studies.

Biomedical journal·2026

Same author

Clinical care guidance in patients with diabetes and metabolic dysfunction-associated steatotic liver disease: A joint consensus.

Hepatology communications·2024

Same author

Metformin-associated lactic acidosis and mortality in type 2 diabetes patients hospitalized with heart failure and/or acute coronary syndrome: A neglected clinical scenario and the potential role of insulin.

International journal of cardiology·2024

Same author

Thiazolidinedione Use Is Associated with a Borderline Lower Risk of Multiple Myeloma and a Significantly Lower Risk of Death in Patients with Type 2 Diabetes Mellitus in Taiwan.

Cancers·2023

Same author

Rosiglitazone has a null association with the risk of prostate cancer in type 2 diabetes patients.

Frontiers in endocrinology·2023

Same author

The Risk of Age-Related Macular Degeneration Is Reduced in Type 2 Diabetes Patients Who Use Metformin.

Pharmaceuticals (Basel, Switzerland)·2023

Search research articles

Related Experiment Video

Updated: May 3, 2026

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

Human insulin does not increase bladder cancer risk.

Chin-Hsiao Tseng¹

¹Department of Internal Medicine, National Taiwan University College of Medicine, Taipei, Taiwan ; Division of Endocrinology and Metabolism, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan ; Division of Environmental Health and Occupational Medicine of the National Health Research Institutes, Taipei, Taiwan.

|January 28, 2014

Summary

This study found no increased bladder cancer risk in patients using human insulin. Careful adjustment for confounding factors is crucial when assessing medication-related cancer risks.

More Related Videos

Magnetic Resonance Imaging Assessment of Carcinogen-induced Murine Bladder Tumors

Magnetic Resonance Imaging Assessment of Carcinogen-induced Murine Bladder Tumors

Published on: March 29, 2019

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

Published on: December 1, 2013

Related Experiment Videos

Last Updated: May 3, 2026

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

Magnetic Resonance Imaging Assessment of Carcinogen-induced Murine Bladder Tumors

Magnetic Resonance Imaging Assessment of Carcinogen-induced Murine Bladder Tumors

Published on: March 29, 2019

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

Published on: December 1, 2013

Area of Science:

Endocrinology
Oncology
Epidemiology

Background:

The potential link between human insulin use and bladder cancer incidence remains under-researched.
Understanding medication-related cancer risks is vital for patient safety and clinical practice.

Purpose of the Study:

To investigate the association between human insulin use and the risk of developing bladder cancer in patients with type 2 diabetes.
To determine if human insulin is a risk factor for bladder cancer.

Main Methods:

A retrospective cohort study utilizing Taiwanese National Health Insurance reimbursement databases (1996-2009).
Followed 785,234 type 2 diabetes patients, excluding pioglitazone users and early insulin glargine use.
Analyzed bladder cancer incidence using Cox regression, calculating hazard ratios for human insulin exposure.

Main Results:

No significant association between human insulin use and bladder cancer was observed after adjusting for all covariates (HR: 1.063; 95% CI: 0.951-1.187).
Initial age-sex-adjusted models showed a significant association (HR: 1.238; 95% CI: 1.122-1.366), which became insignificant with full covariate adjustment.
Dose-response trends were significant in unadjusted models but not after comprehensive covariate adjustment.

Conclusions:

The study suggests that human insulin does not pose a significant risk for bladder cancer.
Highlights the critical importance of adjusting for confounders in epidemiological studies evaluating medication safety.
Reassures patients and clinicians regarding the safety profile of human insulin concerning bladder cancer.